The INTREPID Alliance is a consortium of seven pharmaceutical companies dedicated to accelerating the development of new treatments for emerging pandemic threats that may benefit patients and public health across the globe. The IA is supportive of and contributing to the 100 Days Mission (100 Days Mission June 2021) and the International Pandemic Preparedness Secretariat (IPPS) Science and Technology Group (STEG).
The INTREPID Alliance and to generate listings of antivirals that are:
Preclinical stage compounds that may have utility against eight viral families identified by INTREPID Alliance as having potential to result in a pandemic.
Phase 2-ready that can be quickly deployed into Phase 2/3 clinical trials following the identification of an emerging pandemic (i.e., as proposed by the 100-Days Mission).
In addition, the INTREPID Alliance also provides regular Summaries of the Antiviral Drug Development Landscape that also aids in identifying associated research area gaps.
The “IA 100DM-Ready Clinical Listing” lists new antivirals that are Phase 2-ready and can be quickly deployed into Phase 2/3 clinical trials following the identification of an emerging pandemic (i.e., as proposed by the 100 Days Mission).
The INTREPID Alliance Scientific Working Group (SWG) uses the collective experience of our virologists, medicinal chemists, and drug developers from our member companies to review publicly available data on preclinical phase antiviral compounds with potential utility against future pandemic viruses. The SWG uses the INTREPID Alliance Preclinical Target Compound Profile (TCP) to aid in creating a listing of preclinical compounds that exhibit characteristics consistent with potential as a future clinical candidate.
INTREPID Alliance Scientific Working Group (SWG) uses their Preclinical Target Compound Profile (TCP) and additional resources, such as Target Product Profiles (TPPs) from other groups, to evaluate the characteristics of preclinical and clinical phase compounds. Compounds having characteristics consistent with these resources and that have potential utility against future pandemic viruses may be added to the “IA Clinical Listing” or the “IA Preclinical Compound Listing”.
Virologists, medicinal chemists, and drug developers from our member companies have worked to review antiviral target product profiles (TPPs) from collaborators and to develop an INTREPID Alliance Preclinical Target Compound Profile (TCP). The TPPs generally more closely align with later stage compounds that are/have been in clinical studies may be found elsewhere (e.g., the NIH Antiviral TPPs). The TCPs more specifically define preclinical attributes related to industry-standard criteria for evaluating compounds with therapeutic potential n the pandemic preparedness space.
Listings of promising Phase 2 ready antivirals and preclinical compounds following evaluation by the INTREPID Alliance.
The Antiviral Drug Development Landscape derived from a search of publicly available information, updated monthly.
The INTREPID Alliance conducts an on-going “landscape analysis” by reviewing publicly available information in the antiviral space. The intent of the landscape analysis is to aid identification of clinical (e.g., Phase 2/3 ready) and preclinical antivirals aligned with the 100-Days Mission and to highlight research gaps for the eight viral families with pandemic potential.
The INTREPID Alliance works to generate listings of clinical and preclinical phase compounds that may have utility against twelve viral families identified by IA as having potential to result in a pandemic. It is important to note these do not include vaccines or monoclonal antibodies.